Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 17, 2026

New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now.

View original at nasdaq.com
New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now. Key Points New Fed chair Kevin Warsh wants to shrink the Fed's balance sheet…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stock Advisor has a total average return of 993% compared to 207% for the S&P 500.

    60% confidence
  • Tech stocks with sky-high earnings multiples could see their valuations reduced as higher discount rates are applied to their projected future earnings if the Fed reduces its balance sheet.

    60% confidence
  • Kevin Warsh wants to aggressively reduce the Fed's balance sheet and believes the Fed should use interest rates rather than its balance sheet as a policy tool.

    60% confidence
  • Warsh's desire for a smaller Fed balance sheet means that the Fed Put is somewhat deeper out of the money but remains present in the event of a real crisis.

    60% confidence
  • A shrinking Fed balance sheet won't be catastrophic; markets will adapt over time to any changes under Warsh's leadership.

    60% confidence
  • Investors should reduce exposure to QE-dependent stocks, increase exposure to financials like Berkshire Hathaway, shift bonds to shorter durations, build cash, and maintain a long-term perspective.

    60% confidence
  • The Fed's balance sheet disproportionately helps those with financial assets.

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · benchmark return207 percent
S&P 500 Index Fund · price appreciation6 multiple_x
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now. — Source | Via News | Finance Via News